Cancer Diagnostics Market Size, Share & Growth Forecast 2034: A Comprehensive Overview

Meta Description: The global cancer diagnostics market size was valued at USD 17.24 billion in 2025 and is projected to reach USD 38.27 billion by 2034, growing at a CAGR of 9.5%. Explore key trends, segments, regional insights, and leading players shaping the future of cancer diagnostics.

---

Introduction: Why the Cancer Diagnostics Market Matters Now

Cancer remains one of the most pressing public health challenges of the 21st century. According to the World Health Organization (WHO), new cancer cases globally are expected to reach 35 million by 2050 — a staggering 77% increase from the 20 million cases recorded in 2022. Against this backdrop, the demand for accurate, accessible, and early-stage cancer diagnostics has never been more critical.

The global cancer diagnostics market, as analyzed by Fortune Business Insights, is experiencing robust expansion driven by technological innovation, increasing cancer burden, and growing government awareness initiatives.

---

Cancer Diagnostics Market Size & Growth Forecast

According to the latest report by Fortune Business Insights, the global cancer diagnostics market size was valued at USD 17.24 billion in 2025. It is projected to grow from USD 18.51 billion in 2026 to USD 38.27 billion by 2034, registering a compound annual growth rate (CAGR) of 9.5% during the forecast period of 2026–2034.

This impressive growth trajectory underscores the mounting urgency of early cancer detection, rising healthcare investments worldwide, and the rapid commercialization of next-generation diagnostic technologies.

For a detailed breakdown of market projections, segmentation data, and regional forecasts, refer to the full Cancer Diagnostics Market Size, Share & Industry Analysis Report by Fortune Business Insights.

---

Key Market Drivers

1. Rising Global Cancer Burden

The rising incidence of breast cancer, lung cancer, colorectal cancer, and prostate cancer continues to be the most significant driver of cancer diagnostics market growth. In the United States alone, data from the American Cancer Society indicates that approximately 1,918,030 new cancer cases were projected in 2022, while WHO data estimates actual new cases at 2,380,189 — with around 605,761 deaths in the same year. This rising disease burden directly fuels the need for advanced cancer diagnostics at scale.

2. Government Initiatives and Cancer Screening Programs

Government bodies and health organizations globally are intensifying efforts to promote early diagnosis. Programs such as ACCION (colorectal screening for uninsured Hispanic adults in the U.S.), the Bowel Cancer Screening Programme (BCSP) in the UK, and WHO's Global Strategy for Cervical Cancer Elimination (adopted in August 2020) are expanding diagnostic access and awareness.

Research networks like the Cancer Immunoprevention Network (CIP-Net), the Early Detection Research Network (EDRN), and the Alliance of Glycologists for Cancer Research further support scientific efforts to control cancer.

3. Innovation in Diagnostic Technologies

Market players are investing heavily in next-generation diagnostics. Key developments include:

• In June 2022, F. Hoffmann-La Roche Ltd launched the BenchMark ULTRA PLUS system for cancer diagnosis and targeted patient care.
• In August 2024, Illumina, Inc. received FDA approval for its TruSight Oncology (TSO) comprehensive IVD test, capable of screening over 500 genes and profiling solid tumors in a single test.
• In July 2024, U.S. biotech company Novelna developed a blood protein test capable of identifying 18 early-stage cancers with high accuracy, potentially enabling cost-effective population-wide screening.

4. Artificial Intelligence in Cancer Diagnostics

AI is rapidly becoming a transformative force in cancer diagnostics, particularly for early-stage detection and image analysis. In October 2023, F. Hoffmann-La Roche Ltd partnered with Ibex Medical Analytics and Amazon Web Services to extend AI-powered pathology decision support tools to diagnostic laboratories globally, enhancing detection of prostate and blood cancers.

---

Market Segmentation Analysis

By Product

The assay kits & reagents segment dominates the cancer diagnostics market, accounting for 83.07% of the global market share in 2026. This dominance is driven by the high volume of cancer diagnostic tests conducted globally, frequent new product launches, and the rising need for biomarker-based screening. The instruments segment is also set to grow steadily, supported by increasing healthcare expenditure.

By Technique

• Immunoassays led the market in 2023, owing to their effectiveness in diagnosing breast cancer, prostate cancer, and others. Notably, around 30% of all newly diagnosed cancers in the U.S. are breast cancer, with an estimated 310,720 women and 2,800 men diagnosed in a recent year.
• Immunohistochemistry (IHC) is projected to grow at the fastest CAGR, valued for its precision in cancer subtyping and treatment prediction.
• Molecular diagnostics — encompassing NGS, PCR, and ISH — are pivotal in personalized oncology. In April 2021, Illumina, Inc. partnered with Kartos Therapeutics to develop an NGS-Based TP53 Companion Diagnostic.

By Type

• Tissue biopsy dominates with a 87.04% market share in 2026, favored for its accuracy and molecular profiling capability.
• Liquid biopsy is the fastest-growing segment, valued for speed — an NCBI (2023) study found liquid biopsy NGS results were 26.8 days faster than tissue biopsy results.

By Cancer Type

• Breast cancer held the dominant position in 2023, reflecting the global burden — WHO data shows new breast cancer cases rising from 2.26 million in 2020 to 2.31 million in 2022.
• Lung cancer is expected to grow at the fastest CAGR, driven by rising smoking rates among youth.

By End-User

Clinical laboratories dominated the market in 2023, facilitated by technologically advanced equipment and the approximately 4 billion laboratory tests conducted annually in the U.S. (NCBI, 2024). Hospitals & clinics are also growing rapidly as patients increasingly prefer integrated diagnosis and treatment.

---

Regional Outlook

North America leads thanks to the strong presence of players like Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare, alongside widespread precision oncology adoption. The U.S. market alone is projected at USD 6.21 billion in 2026.

Asia Pacific is the fastest-growing region, propelled by China's massive cancer burden (4.82 million cases in 2022 per WHO), India's expanding healthcare infrastructure, and Japan's focus on personalized medicine. China's 2026 market is forecast at USD 1.67 billion; India's at USD 0.67 billion.

Europe benefits from landmark programs like the UK's 100,000 Genomes Project (studying 13,000+ tumor samples) and partnerships like Bayer AG + Thermo Fisher (March 2024) for NGS-based companion diagnostics.

---

Competitive Landscape

The cancer diagnostics market is highly competitive, with key players including:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Illumina, Inc. (U.S.)
• GE Healthcare (U.S.)
• BD (U.S.)
• bioMérieux SA (France)
• Myriad Genetics, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• QIAGEN (Germany)

Notable recent developments include Myriad Genetics' launch of Precise Solutions (March 2024) for precision oncology, Abbott's FDA approval of the Alinity m HR HPV assay for cervical cancer screening (November 2023), and Bio-Rad's launch of the ddPLEX ESR1 Mutation Detection Kit (April 2024).

---

Challenges Restraining Market Growth

Despite strong growth momentum, the cancer diagnostics market faces notable headwinds:

• High costs: A PCR machine can range from USD 3,000 to USD 30,000, with additional maintenance expenses — limiting adoption in low-resource settings.
• Risk factors in procedures: Colonoscopy, a gold standard for colorectal cancer, carries risks including bleeding, perforation, and device-associated infections.
• Limited infrastructure in emerging markets: Countries in parts of Asia, Africa, and Latin America face barriers in acquiring advanced diagnostics due to economic constraints and shortage of trained professionals.
• Regulatory fragmentation: Differing regulatory frameworks across regions slow the introduction of innovative diagnostic tools.
• Supply chain and trade tensions: Global trade restrictions can hinder access to diagnostic equipment, particularly in developing markets.

---

Conclusion

The cancer diagnostics market is on a clear growth trajectory — from USD 17.24 billion in 2025 to USD 38.27 billion by 2034 — driven by a convergence of rising cancer incidence, technological advancement, AI integration, and expanding government support. As liquid biopsies, NGS platforms, and AI-powered pathology tools mature, early and accurate cancer diagnosis will become more accessible globally.

To access the complete Cancer Diagnostics Market Size, Share & Forecast Report (2026–2034), including detailed segmentation, competitive benchmarking, and regional data, visit the full report on Fortune Business Insights.

---

Source: Cancer Diagnostics Market Size, Share & Industry Analysis — Fortune Business Insights